

## LISTING OF THE CLAIMS

1-10. (canceled)

11. (withdrawn) A recombinant adenovirus containing an expression vector comprising P972 gene and a promoter operably linked to the P972 gene, wherein said adenovirus is capable of infecting mammalian cells.

12. (withdrawn) The recombinant adenovirus of claim 11, wherein the adenovirus is AdP972 and has Accession No. KCTC 0806BP.

13. (withdrawn) The recombinant adenovirus of claim 11, wherein the P972 gene is wild-type human P972 cDNA.

14. (withdrawn) A mammalian cell transformed with the adenovirus of claim 11.

15. (withdrawn) The mammalian cell of claim 14, wherein the cell is a human cell.

16. (withdrawn) The mammalian cell of claim 15 wherein the cell is a cancer cell.

17. (withdrawn) The human cell of claim 15, wherein the cell is a cancer cell.

18. (withdrawn) The human cell of claim 15, wherein the cancer cell is selected from a breast cancer cell, a colon cancer cell or a cervical cancer cell.

19. (currently amended) A method of treating cancer in a mammal in need thereof, comprising directly administering to the mammal an effective amount of ~~the~~ a recombinant adenovirus of claim 11 containing an expression vector comprising P972 gene and a promoter operably linked to the P972 gene, wherein said adenovirus is capable of infecting mammalian cells.

20. (currently amended) A method of treating cancer in a mammal in need thereof, comprising directly administering to the mammal ~~the a~~ a recombinant adenovirus ~~of claim 12~~, wherein the adenovirus is AdP972 and has Accession No. KCTC 0806BP.

21. (New) The method of claim 19, wherein the cancer is selected from the group consisting of cervical cancer, breast cancer, and colon cancer.

22. (New) The method of claim 21, wherein the cancer is cervical cancer.

23. (New) The method of claim 21, wherein the cancer is breast cancer.

24. (New) The method of claim 23, wherein the breast cancer tumor cells express the estrogen receptor.

25. (New) The method of claim 23, wherein the breast cancer is metastatic breast cancer.

26. (New) The method of claim 21, wherein the cancer is colon cancer.

27. (New) The method of claim 26, wherein the colon cancer is metastatic colon cancer.

28. (New) A method of inhibiting the growth of a mammalian tumor cell comprising contacting the tumor cell with an effective amount of a recombinant adenovirus containing an expression vector comprising P972 gene and a promoter operably linked to the P972 gene, wherein said adenovirus is capable of infecting the tumor cell.

29. (New) The method of claim 28, wherein the tumor cell is selected from the group consisting of a cervical tumor cell, a breast tumor cell, and a colon tumor cell.

30. (New) The method of claim 29, wherein the tumor cell is breast tumor cell which expresses the estrogen receptor.

31. (New) The method of claim 30, wherein the breast tumor cell is metastatic.

32. (New) The method of claim 29, wherein the tumor cell is a colon tumor cell.

33. (New) The method of claim 32, wherein the colon tumor cell is metastatic.

34. (New) The method of claim 24, wherein the inhibiting tumor cell growth is *in vivo*.

35. (New) The method of claim 28, wherein the growth inhibition results in tumor regression.

36. (New) The method of claim 35, wherein the tumor regression occurs *in vivo*.

37. (New) The method of claim 28, wherein the adenovirus is AdP972 and has Accession No. KCTC 0806BP.